Efficacy and safety of telitacicept as an add-on therapy for relapsing lupus nephritis: a retrospective cohort study
AimThis study aims to evaluate the efficacy and safety of telitacicept addition to standard therapy in adults with relapsing lupus nephritis (LN).MethodsFrom 2021 to 2024, patients with relapsing LN were identified and divided into two groups based on telitacicept administration. Laboratory indicato...
Uloženo v:
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2026-05-01
|
| Edice: | Frontiers in Immunology |
| Témata: | |
| On-line přístup: | https://www.frontiersin.org/articles/10.3389/fimmu.2026.1826829/full |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|